Biozeus Biopharmaceutical S.A.

Biozeus is a drug development company. We identify early-stage drug candidates from leading Brazilian research institutions and develop them into new therapies for improving and saving lives, worldwide. BZ 371 platform are NO synthase (NOS) enhancers, acting locally by topical application, restoring physiological NO production, without systemic exposure. This novel and unique mechanism of action offers a more constant, safer and prolonged NO supply, solving problems that have plagued NO-based drug development. Currently, Biozeus have 4 products development lines in late pre clinical/early clinical development: 1. OPHTHALMOLOGY - BZ371 peptide eye drop for the treatment of GLAUCOMA and for NAION (rare disease) based on IOP reduction and neuroprotective effect around the optical nerve head. 2. PULMONARY - BZ371B inhalation reduces pulmonary arterial hypertension (PAH), even in PAH related to COPD. BZ371B bronchodilatation and anti-inflammatory effect has the potential to be used in other pulmonary diseases like COPD, Asthma and SARS. 3. SEXUAL DISFUNCTION - BZ371A topical use cause cavernosal corpus blood flow increase, even in ERECTILE DISFUNCTION subjects that do not responde to PDE5i (like Viagra). The combination of BZ371A and PDE5is also achieve sinergistic effect. BZ371A also has the potential to be used in FEMALE SEXUAL AROUSAL DISORDERS. 4. DERMATOLOGY – the antimicrobial effect of NO local production can act on ACNE and MOLLUSCUS VULGARIS. Antiinflamatory local effect can act on PSORIASIS and DERMATITES as well. See our video in https://youtu.be/noCkk3UndIs